keyword
MENU ▼
Read by QxMD icon Read
search

Erlotinib

keyword
https://www.readbyqxmd.com/read/29691367/upregulation-of-sall4-by-egfr-activation-regulates-the-stemness-of-cd44-positive-lung-cancer
#1
Wenjing Du, Lan Ni, Baojun Liu, Ying Wei, Yubao Lv, Sujing Qiang, Jingcheng Dong, Xijun Liu
The transcriptional factor SALL4, an important stem cell regulator, is expressed in hematopoietic stem cells and various malignancies, but its role in EGFR-mutated NSCLCs has not been studied yet. Here, we report that the expression of Sal-like protein 4 (SALL4), was significantly higher in EGFR mutated lung tumors than in non-tumor tissue. SALL4-high lung cancer patients had poorer prognosis after surgery than SALL4-low patients. The expression of SALL4 could be induced by the activation of EGFR through the extracellular signal-regulated kinase 1/2 (ERK1/2) signaling pathway...
April 25, 2018: Oncogenesis
https://www.readbyqxmd.com/read/29689091/higher-expression-of-mir-133b-is-associated-with-better-efficacy-of-erlotinib-as-the-second-or-third-line-in-non-small-cell-lung-cancer-patients
#2
Alessandra Bisagni, Maria Pagano, Sally Maramotti, Francesca Zanelli, Martina Bonacini, Elena Tagliavini, Luca Braglia, Massimiliano Paci, Andrea Mozzarelli, Stefania Croci
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (gefitinib, erlotinib and afatinib) are indicated as first-line therapy in patients with non-small cell lung cancer (NSCLC) whose tumors harbor activating mutations in the EGFR gene. Erlotinib is also used in second and third-line therapy for patients whose tumors have wild type EGFR but to date there are no validated biomarkers useful to identify which patients may benefit from this treatment. The expression level of four miRNAs: miR-133b, -146a, -7 and -21 which target EGFR was investigated by real-time PCR in tumor specimens from NSCLC patients treated with erlotinib administered as the second or third line...
2018: PloS One
https://www.readbyqxmd.com/read/29687154/erlotinib-in-routine-clinical-practice-for-first-line-maintenance-therapy-in-patients-with-advanced-non-small-cell-lung-cancer-nsclc
#3
M Faehling, J Achenbach, P Staib, U Steffen, H W Tessen, V E Gaillard, W Brugger
PURPOSE: The controlled phase III trial SATURN demonstrated that maintenance therapy with erlotinib after the first-line platinum-based chemotherapy prolonged progression-free survival (PFS) and overall survival (OS) of non-small cell lung cancer (NSCLC) patients with advanced, non-progressive disease. We conducted the non-interventional study SATURN NIS to investigate the effectiveness and tolerability of erlotinib maintenance in daily clinical practice. METHODS: This single-arm NIS screened 290 patients with locally advanced or metastatic NSCLC (stage IIIB or IV) and stable disease after standard platinum-based first-line chemotherapy in 95 institutions across Germany...
April 23, 2018: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29685880/integrative-kinome-profiling-identifies-mtorc1-2-inhibition-as-treatment-strategy-in-ovarian-clear-cell-carcinoma
#4
Joseph J Caumanns, Katrien Berns, G Bea A Wisman, Rudolf S N Fehrmann, Tushar Tomar, Harry Klip, Gert Jan Meersma, E Marielle Hijmans, Annemiek Gennissen, Evelien W Duiker, Desiree Weening, Hiroaki Itamochi, Roelof Jc Kluin, An K L Reyners, Michael J Birrer, Helga B Salvesen, Ignace Vergote, Els Van Nieuwenhuysen, James D Brenton, Elena I Braicu, Jolanta Kupryjanczyk, Beata Spiewankiewicz, Lorenza Mittempergher, Rene Bernards, Ate G J van der Zee, Steven de Jong
PURPOSE: Advanced stage ovarian clear cell carcinoma (OCCC) is unresponsive to conventional platinum-based chemotherapy. Frequent alterations in OCCC include deleterious mutations in the tumor suppressor ARID1A and activating mutations in the PI3K subunit PIK3CA. In this study, we aimed to identify currently unknown mutated kinases in OCCC patients and test druggability of downstream affected pathways in OCCC models. EXPERIMENTAL DESIGN: In a large set of OCCC patients (n=124), the human kinome (518 kinases) and additional cancer related genes were sequenced and copy number alterations were determined...
April 23, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29682186/novel-drug-resistance-mechanisms-of-pemetrexed-treated-non-small-cell-lung-cancer
#5
Ryosuke Tanino, Yukari Tsubata, Nanae Harashima, Mamoru Harada, Takeshi Isobe
Pemetrexed (PEM) improves the overall survival of patients with advanced non-small cell lung cancer (NSCLC) when administered as maintenance therapy. However, PEM resistance often appears during the therapy. Although thymidylate synthase is known to be responsible for PEM resistance, no other mechanisms have been investigated in detail. In this study, we explored new drug resistance mechanisms of PEM-treated NSCLC using two combinations of parental and PEM-resistant NSCLC cell lines from PC-9 and A549. PEM increased the apoptosis cells in parental PC-9 and the senescent cells in parental A549...
March 30, 2018: Oncotarget
https://www.readbyqxmd.com/read/29680500/cross-talk-between-egfr-and-il-6-drives-oncogenic-signaling-and-offers-therapeutic-opportunities-in-cancer
#6
Kriti Ray, Beata Ujvari, Venkata Ramana, John Donald
Epidermal growth factor receptor (EGFR) is a known target in cancer therapy and targeting the receptor has proven to be extremely successful in treating cancers that are dependent on EGFR signaling. To that effect, targeted therapies to EGFR such as Cetuximab, Panitumumab-monoclonal antibodies and Gefitinib, Erlotinib-tyrosine kinase inhibitors have had success in therapeutic scenarios. However, the development of resistance to these drugs makes it necessary to combine anti- EGFR therapies with other inhibitors, so that resistance can be overcome by the targeting of alternate signaling pathways...
April 7, 2018: Cytokine & Growth Factor Reviews
https://www.readbyqxmd.com/read/29679689/bovine-serum-albumin-binding-study-to-erlotinib-using-surface-plasmon-resonance-and-molecular-docking-methods
#7
Parvin Taghipour, Mostafa Zakariazadeh, Maryam Sharifi, Jafar Ezzati Nazhad Dolatabadi, Abolfazl Barzegar
Bovine serum albumin (BSA) is the most abundant protein in the blood circulation and it is commonly used for drug delivery in blood. Therefore, we aim to study BSA interaction with erlotinib as an anticancer drug using surface plasmon resonance (SPR) and molecular modeling methods under physiological conditions (pH = 7.4). BSA immobilized on carboxymethyl dextran hydrogel Au chip (CMD) after activation with N-hydroxysuccinimide and N-ethyl-N-(3-diethylaminopropyl) carbodiimide and then the erlotinib binding to BSA at different concentrations was evaluated...
April 9, 2018: Journal of Photochemistry and Photobiology. B, Biology
https://www.readbyqxmd.com/read/29675860/pulmonary-pleomorphic-carcinoma-a-case-harboring-egfr-mutation-treated-with-egfr-tkis
#8
Ken Masuda, Takaaki Tokito, Koichi Azuma, Eriko Yanagida, Masayuki Nakamura, Yoshiko Naito, Norikazu Matsuo, Hidenobu Ishii, Kazuhiko Yamada, Jun Akiba, Tomoaki Hoshino
Pulmonary pleomorphic carcinoma (PPC) is a very rare type of primary lung cancer with an aggressive clinical course. Few reports have documented therapeutic options for PPC with EGFR mutations. Herein, we report a case of PPC with EGFR mutation treated with EGFR-tyrosine kinase inhibitors (TKIs). A 65-year-old Japanese woman was diagnosed with stage IV lung adenocarcinoma with L858R point mutation in exon 21. Despite treatment with erlotinib, the patient died after two weeks as a result of rapid disease progression...
April 19, 2018: Thoracic Cancer
https://www.readbyqxmd.com/read/29672751/a-bicenter-study-on-adjuvant-surgery-following-treatment-with-tyrosine-kinase-inhibitors-in-patients-with-advanced-lung-adenocarcinoma
#9
Ludovic Fournel, Pierre-Emmanuel Falcoz, Audrey Mansuet-Lupo, Elena Garelli, Filippo Lococo, Marco Alifano
OBJECTIVES: A small number of patients with advanced pulmonary adenocarcinomas treated with tyrosine kinase inhibitors (TKIs) was subsequently considered eligible for surgery. Our goal was to report the clinical characteristics, pathological features and prognosis of these patients with the aim of exploring the feasibility of this strategy of care. METHODS: We retrospectively reviewed the medical files of 19 patients in whom systemic treatment, including TKIs, resulted in a possible stabilization of the disease such that they were considered eligible for surgery (adjuvant surgery)...
April 16, 2018: Interactive Cardiovascular and Thoracic Surgery
https://www.readbyqxmd.com/read/29669181/racial-disparity-in-oncologic-and-quality-of-life-outcomes-in-patients-with-locally-advanced-head-and-neck-squamous-cell-carcinomas-enrolled-in-a-randomized-phase-2-trial
#10
Margaret K Guerriero, Mary W Redman, Kelsey K Baker, Renato G Martins, Keith Eaton, Laura Q Chow, Rafael Santana-Davila, Christina Baik, Bernardo H Goulart, Sylvia Lee, Cristina P Rodriguez
BACKGROUND: To better understand patient-reported quality of life (PRQOL) for patients with head and neck cancer, PRQOL scores were collected in a clinical trial. METHODS: Patients were randomized to arm A (70 Gy of radiation with cisplatin) or arm B (70 Gy of radiation with cisplatin plus erlotinib at 150 mg daily). PRQOL scores were measured on days -7 (arm B only), 0, 30, and 180 with the University of Washington Quality of Life Questionnaire. Associations with clinical factors and outcomes were explored with linear mixed, logistic, and Cox regression models...
April 18, 2018: Cancer
https://www.readbyqxmd.com/read/29668619/gefitinib-provides-similar-effectiveness-and-improved-safety-than-erlotinib-for-advanced-non-small-cell-lung-cancer-a-meta-analysis
#11
Wenxiong Zhang, Yiping Wei, Dongliang Yu, Jianjun Xu, Jinhua Peng
BACKGROUND: The epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and erlotinib are effective for advanced non-small cell lung cancer (NSCLC). This meta-analysis compared their effectiveness and safety. METHODS: We searched systematically in PubMed, ScienceDirect, The Cochrane Library, Scopus, Ovid MEDLINE, EMBASE, Web of Science, and Google Scholar for relevant clinical trials regarding gefitinib versus erlotinib for NSCLC. Antitumor effectiveness (overall survival [OS], progression-free survival [PFS], objective response rate [ORR] and disease control rate [DCR]) and adverse effects [AEs]) were assessed...
April 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29660496/quantitative-targeted-proteomic-analysis-of-potential-markers-of-tyrosine-kinase-inhibitor-tki-sensitivity-in-egfr-mutated-lung-adenocarcinoma
#12
Shivangi Awasthi, Tapan Maity, Benjamin L Oyler, Yue Qi, Xu Zhang, David R Goodlett, Udayan Guha
Lung cancer causes the highest mortality among all cancers. Patients harboring kinase domain mutations in the epidermal growth factor receptor (EGFR) respond to EGFR tyrosine kinase inhibitors (TKIs), however, acquired resistance always develops. Moreover, 30-40% of patients with EGFR mutations exhibit primary resistance. Hence, there is an unmet need for additional biomarkers of TKI sensitivity that complement EGFR mutation testing and predict treatment response. We previously identified phosphopeptides whose phosphorylation is inhibited upon treatment with EGFR TKIs, erlotinib and afatinib in TKI sensitive cells, but not in resistant cells...
April 13, 2018: Journal of Proteomics
https://www.readbyqxmd.com/read/29660315/metronomic-vinorelbine-is-directly-active-on-non-small-cell-lung-cancer-cells-and-sensitizes-the-egfr-l858r-t790m-cells-to-reversible-egfr-tyrosine-kinase-inhibitors
#13
Paola Orlandi, Teresa Di Desidero, Giada Salvia, Beatrice Muscatello, Giulio Francia, Guido Bocci
Metronomic vinorelbine (mVNR) has been described primarily as an antiangiogenic therapy, and no direct effects of mVNR on Non Small Cell Lung Cancer (NSCLC) cells has yet been demonstrated. The aims of this study were i) to establish the direct activity of mVNR on NSCLC cells either EGFR wt or EGFRL858R/T790M , and ii) to quantify the synergism of the combination with reversible EGFR tyrosine kinase inhibitors (TKIs), investigating the underlying mechanism of action. Proliferation assays were performed on A-549 (EGFR-wthigh ), H-292 (EGFR-wt), H-358 (EGFR-wt), H-1975 (EGFRL858R/T790M ) NSCLC cell lines exposed to mVNR, its active metabolite deacetyl-VNR (D-VNR), gefitinib and erlotinib for 144h treatments...
April 13, 2018: Biochemical Pharmacology
https://www.readbyqxmd.com/read/29658816/a-mixed-treatment-comparison-of-toxicity-of-gemcitabine-combined-with-different-targeted-drugs-in-the-treatment-of-advanced-or-metastatic-pancreatic-cancer
#14
Penpa Dorjee, Zi-Wen Long
The mixed treatment comparison study was performed in order to compare the toxicities of Gemcitabine and different targeted drug combinations in the treatment of advanced/metastatic pancreatic cancer (PC). Searches were performed from the inception of PubMed and Cochrane Library databases to February 2017. This study included randomized controlled trials (RCTs) of Gemcitabine and different targeted drug combinations in the treatment of advanced/metastatic PC. Odds ratio (OR) values were calculated by direct and indirect comparisons, and the surface under the cumulative ranking curves (SUCRA) were drawn...
April 16, 2018: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/29656750/afatinib-in-heavily-pretreated-advanced-nsclc-patients-who-progressed-following-prior-gefitinib-or-erlotinib-compassionate-use-program-in-korea
#15
Moon Ki Choi, Jin Seok Ahn, Young-Chul Kim, Byoung Chul Cho, In-Jae Oh, Sang-We Kim, Jong Seok Lee, Joo-Hang Kim, Myung-Ju Ahn, Keunchil Park
INTRODUCTION: Afatinib, an irreversible ErbB family blocker, approved for first-line treatment of epidermal growth factor receptor (EGFR) mutated advanced non-small cell lung cancer (NSCLC). This study investigated experience of afatinib within a compassionate use program (CUP). METHODS: The afatinib CUP was an open-label, multicenter, single-arm program in Korea. We enrolled patients with stage IV NSCLC and who had received at least one line of previous cytotoxic chemotherapy and previous EGFR TKI treatment with either an EGFR mutation or documented clinical benefit...
May 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29650685/osimertinib-a-novel-dermatologic-adverse-event-profile-in-patients-with-lung-cancer
#16
Chia-Yu Chu, Jennifer Choi, Beth Eaby-Sandy, Corey J Langer, Mario E Lacouture
Dermatologic adverse events (dAEs) are common with the use of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy. First- and second-generation agents (erlotinib, gefitinib, and afatinib) are frequently associated with acneiform rash, pruritus, xerosis, and paronychia; the incidence and characterization of these dAEs have been well described. However, there is evidence that the dAE profile is different with third-generation EGFR-TKIs. Herein, we describe the dAEs associated with third-generation EGFR-TKIs and our clinical experience with osimertinib, a third-generation EGFR-TKI approved by the U...
April 12, 2018: Oncologist
https://www.readbyqxmd.com/read/29645086/erlotinib-plus-either-pazopanib-or-placebo-in-patients-with-previously-treated-advanced-non-small-cell-lung-cancer-a-randomized-placebo-controlled-phase-2-trial-with-correlated-serum-proteomic-signatures
#17
David R Spigel, Howard A Burris, F Anthony Greco, Kent C Shih, Victor G Gian, Andrew J Lipman, Davey B Daniel, David M Waterhouse, Lindsey Finney, John V Heymach, John D Hainsworth
BACKGROUND: This study compared the efficacy and safety of treatment with erlotinib plus pazopanib versus erlotinib plus placebo in patients with previously treated advanced non-small cell lung cancer (NSCLC). METHODS: Patients with progressive-stage IV NSCLC after either 1 or 2 previous chemotherapy regimens were randomized to receive erlotinib (150 mg by mouth daily) with either pazopanib (600 mg by mouth daily) or placebo. During treatment, patients were evaluated every 8 weeks until disease progression or unacceptable toxicity...
April 12, 2018: Cancer
https://www.readbyqxmd.com/read/29618618/inositol-trisphosphate-receptor-type-3-mediated-enhancement-of-egfr-and-met-co-targeting-efficacy-in-non-small-cell-lung-cancer-detected-by-18f-fluorothymidine
#18
Francesca Iommelli, Viviana De Rosa, Cristina Terlizzi, Marcello Monti, Mariarosaria Panico, Rosa Fonti, Silvana Del Vecchio
PURPOSE: Our aim was to test whether imaging with 18 F-fluorothymidine (18 F-FLT) PET/CT was able to detect the combined effects of EGFR and MET inhibitors in oncogene-driven non-small lung cancer (NSCLC) and to elucidate the mechanisms underlying the enhanced efficacy of drug combination. EXPERIMENTAL DESIGN: NSCLC cells bearing MET amplification (H1993 and H820) were treated with EGFR and MET inhibitors either alone or in combination and then tested for cell viability and inhibition of signaling...
April 4, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29616327/whole-exome-sequencing-identifies-key-mutated-genes-in-t790m-wildtype-cmet-unamplified-lung-adenocarcinoma-with-acquired-resistance-to-first-generation-egfr-tyrosine-kinase-inhibitors
#19
Chenguang Li, Hailin Liu, Bin Zhang, Liqun Gong, Yanjun Su, Zhenfa Zhang, Changli Wang
PURPOSE: Lung cancer is the leading cause of cancer-related death worldwide. Lung adenocarcinoma harboring EGFR-activating mutations will inevitably acquire resistance to first-generation EGFR tyrosine kinase inhibitors (TKIs). EGFR T790M mutation and cMET amplification are common mechanisms. Further study is needed to explore unknown genomic alterations contributing to drug resistance. METHODS: Tumor and blood samples from 69 stage IIIB-IV NSCLC patients defined as acquired resistance to first-generation EGFR TKIs (gefitinib, erlotinib or ecotinib) were collected...
April 3, 2018: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29616128/egfr-tki-resistance-and-map17-are-associated-with-cancer-stem-cell-like-properties
#20
Yi Shao, Hui Lv, Dian-Sheng Zhong, Qing-Hua Zhou
Patients with non-small-cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (EGFR) mutations generally react well to tyrosine kinase inhibitors (TKIs). However acquired resistance eventually occurs. Several mechanisms contribute to the resistance including T790M mutation, c-Met amplification and PIK3CA mutation. In recent years, cancer stem cells (CSCs) have been suggested to be involved in TKI resistance. MAP17 is aberrantly overexpressed in a number of malignancies. However, the expression pattern and function of MAP17 in CSCs are still unclear...
May 2018: Oncology Letters
keyword
keyword
8876
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"